Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 90-97

  Zhan, Wang ^a   Kang, Gail A ^b,c   Glass, Graham A ^b,c   Zhang, Yu ^a   Shirley, Cheryl ^a   Millin, Rachel ^a   Possin, Katherine L ^c   Nezamzadeh, Marzieh ^a   Weiner, Michael W ^a   Marks, William J ^b,c   Schuff, Norbert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diffusion tensor imaging; Magnetic resonance imaging; Parkinson's disease; Subtypes

Indexed keywords

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; DISEASE SEVERITY; FRACTIONAL ANISOTROPY; FRONTAL LOBE; HUMAN; MALE; MOTOR CORTEX; MOTOR DYSFUNCTION; PARKINSON DISEASE; PREMOTOR CORTEX; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; SUPPLEMENTARY MOTOR AREA; THALAMUS; UNIFIED PARKINSON DISEASE RATING SCALE; WHITE MATTER;

AGED; BRAIN; BRAIN MAPPING; DIFFUSION TENSOR IMAGING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84855933194     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23917     Document Type: Article

References (47)

1. Factor SA, Weiner WJ. Parkinson's Disease: Diagnosis and Clinical Management. 2nd ed. New York: Demos Medical Publishing; 2002.
2. Rudow G, O'Brien R, Savonenko AV, et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease, Acta Neuropathol. 2008; 115: 461-470.
3. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 1985; 35: 1215-1218.
4. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009; 117: 63-73.
5. Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx. 2004; 1: 243-254.
6. Burn DJ, O'Brien JT. Use of functional imaging in Parkinsonism and dementia. Mov Disord. 2003; 18( Suppl 6): S88-S95.
7. Nikolaus S, Antke C, Müller HW. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res. 2009; 204: 32-66.
8. Au WL, Adams JR, Troiano A, Stoessl AJ. Neuroimaging in Parkinson's disease. J Neural Transm Suppl. 2006; 70: 241-248.
9. Assaf Y, Pasternak O. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci. 2008; 34: 51-61.
10. Lang AE, Mikulis D. A new sensitive imaging biomarker for Parkinson disease? Neurology. 2009; 72: 1374-1375.
11. Chan LL, Rumpel H, Yap K, et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78: 1383-1386.
12. Boska MD, Hasan KM, Kibuule D, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis. 2007; 26: 590-596.
13. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage. 2009; 47: 435-441.
14. Zhang K, Yu C, Zhang Y, et al. Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. Eur J Radiol. 2011; 77: 269-273.
15. Degirmenci B, Yaman M, Haktanir A, Albayrak R, Acar M, Caliskan G. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease. Neurosci Lett. 2007; 416: 294-298.
16. Van Camp N, Blockx I, Verhoye M, et al. Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract. NMR Biomed. 2009; 22: 697-706.
17. Kendi AK, Lehericy S, Luciana M, Ugurbil K, Tuite P. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol. 2008; 29: 501-505.
18. Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain. 2006; 129: 538-542.
19. Nicoletti G, Tonon C, Lodi R, et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Mov Disord. 2008; 23: 2370-2376.
20. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009; 72: 1378-1384.
21. Antoniades CA, Barker RA. The search for biomarkers in Parkinson's disease: a critical review. Expert Rev Neurother. 2008; 8: 1841-1852.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
23. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord. 2005; 20: 1133-1142.
24. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003; 18: 738-750.
25. Schiess MC, Zheng H, Soukup VM, Bonnen JG, Nauta HJ. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord. 2000; 6: 69-76.
26. Griswold MA, Jakob PM, Heidemann RM, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med. 2002; 47: 1202-1210.
27. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006; 31: 1487-1505.
28. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System-An Approach to Cerebral Imaging. New York: Thieme Medical Publishers; 1988.
29. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002; 15: 1-25.
30. Howell, DC. Statistical Methods for Psychology. 5th ed. Wadsworth Publishing; 2001.
31. Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab. 1992; 12: 900-918.
32. Frank E Harrell, Jr. Regression Modeling Strategies. New York: Springer-Verlag Inc.; 2001.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57: 289-300.
34. Cheron G, Dan B, Borenstein S. Sensory and motor interfering influences on somatosensory evoked potentials. J Clin Neurophysiol. 2000; 17: 280-294.
35. Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl. 2002; 62: 347-376.
36. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry. 2004; 75: 481-484.
37. Kurlan RM. Parkinson's Disease and Nonmotor Dysfunction. Totowa, NJ: Humana Press; 2005.
38. Pelled G, Bergman H, Ben-Hur T, Goelman G. Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson's disease rat model: a functional MRI study. Eur J. Neurosci. 2005; 21: 2227-2232.
39. Schneider JS, Diamond SG, Markham CH. Deficits in orofacial sensorimotor function in Parkinson's disease. Ann Neurol. 1986; 19: 275-282.
40. Lewis SJ, Barker RA. Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity. J Clin Neurosci. 2009; 16: 620-625.
41. Brooks DJ. The role of the basal ganglia in motor control: contributions from PET. J Neurol Sci. 1995; 128: 1-13.
42. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update. Trends Neurosci. 1996; 19: 417-422.
43. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 62: 133-140.
44. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995; 38: 589-598.
45. Rauschecker JP. Compensatory plasticity and sensory substitution in the cerebral cortex. Trends Neurosci. 1995; 18: 36-43.
46. Mallol R, Barrós-Loscertales A, López M, Belloch V, Parcet MA, Avila C. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of prelearned sequential movements. Brain Res. 2007; 1147: 265-271.
47. Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995; 37: 680-686.